TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00645684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Anastomosis
Description: Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Anastomosis
Description: Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
Study: NCT02687178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canrenone 50 vs canrenone 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canrenone 50 vs canrenone 100 mg
Study: NCT01867112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity either by individualized program or general guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity either by individualized program or general guidelines
Study: NCT03964844

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02091219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2400 IU/day by mouth for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25(OH)D3
Description: 20 micrograms/day by mouth for 16 weeks
Study: NCT00234910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: TDF 300mg QD for 72 wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir with 2 Nucleoside RTIs
Description: LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir with 2 Nucleoside RTIs
Description: LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
Study: NCT01257802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot leuprolide acetate 3.75 mg
Description: Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
Study: NCT03674424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Chemotherapy with or without avelumab followed by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Chemotherapy with or without avelumab followed by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Chemotherapy with or without avelumab followed by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Chemotherapy with or without avelumab followed by surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystectomy
Description: Cystectomy 3 to 6 weeks after last administration of chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystectomy
Description: Cystectomy 3 to 6 weeks after last administration of chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystectomy
Description: Cystectomy 3 to 6 weeks after last administration of chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystectomy
Description: Cystectomy 3 to 6 weeks after last administration of chemotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CG
Description: Chemotherapy 4 cycles of 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DD-MVAC
Description: Chemotherapy 4 cycles of 2 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PG
Description: Chemotherapy 2 cycles of 4 weeks
Study: NCT02829918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
Study: NCT03708068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early exclusive enteral nutrition
Description: Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
Study: NCT04636086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04284748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercise with blood flow restriction
Description: Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
Study: NCT03825198

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NaCL 0,9%
Description: 20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Study: NCT04284748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric exercise
Description: Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy program
Description: Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy program
Description: Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
Study: NCT01763736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: playlist per patient preference
Study: NCT01594060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, regular - act rapid
Description: 4 shots of regular insulin: 3 before meals and one at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine, Insulin glargine
Description: 1 shot glargine at bedtime 3 shots glulisine before meals
Study: NCT02390297

Intervention type: GENETIC
Intervention: Blood tests
Description: Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
Study: NCT04455724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure incisional wound therapy
Description: A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sterile dressing
Description: A standard, sterile island dressing
Study: NCT03825198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: induction agent for general anaesthesia ( 2-3 mg/kg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: propofol
Description: induction agent for general anaesthesia ( 2-3 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: muscle relaxant used during general anaesthesia ( 0,5 mg/kg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rocuronium Bromide
Description: muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
Study: NCT01027871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
Study: NCT00244257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMA161
Description: 3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
Study: NCT03589482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
Study: NCT03825198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: inhalation aesthetic used for the maintenance of general anaesthesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sevoflurane
Description: inhalation aesthetic used for the maintenance of general anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: postoperative drug for analgesia ( 1 gram 4/day)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paracetamol
Description: postoperative drug for analgesia ( 1 gram 4/day)
Study: NCT03589482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ExPRESS-derived PEEP level
Description: The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
Study: NCT02109679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: multiple doses metformin given as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: multiple doses BI 187004 given as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: multiple doses BI 187004 given as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: multiple doses metformin given as tablet
Study: NCT00550108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol lavage
Description: Ethanol lavage of pancreatic cysts.
Study: NCT04229004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine combined with nab-paclitaxel
Description: Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose -mFOLFIRINOX
Description: The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
Description: Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
Description: Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Dose -SM-88
Description: Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.
Study: NCT03888924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin vaccine
Description: One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic solution of sodium chloride (2mL vials).
Study: NCT03621592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed® Sorbact®
Description: Dialkylcarbomoyl chloride based wound dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acticoat®
Description: Silver impregnated contact layer dressing
Study: NCT03834272

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device.
Study: NCT03825198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketorolac
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine pca
Description: postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: morphine pca
Description: postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Study: NCT04283123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Bidet
Description: During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
Study: NCT03825198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: drug given during general anaesthesia to prevent postoperative nausea

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: drug given during general anaesthesia to prevent postoperative nausea
Study: NCT04283123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Waitlist control
Study: NCT05895630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive physical exercise
Description: Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video physical exercise
Description: Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
Study: NCT03436654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg daily orally
Study: NCT03825198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: loading dose morhine 0,1 mg/kg at the end of surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morphine
Description: loading dose morhine 0,1 mg/kg at the end of surgery
Study: NCT03757520

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain Pressure Threshold
Description: The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain Pressure Threshold
Description: The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected.
Study: NCT04245033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
Study: NCT03436654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000mg daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg BID orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.